MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
5.13
+0.14 (2.81%)
May 19, 2025, 3:52 PM - Market open
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $1.93M in the quarter ending March 31, 2025, with 176.33% growth. This brings the company's revenue in the last twelve months to $34.51M, up 203.23% year-over-year. In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth.
Revenue (ttm)
$34.51M
Revenue Growth
+203.23%
P/S Ratio
10.64
Revenue / Employee
$90,572
Employees
381
Market Cap
412.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MGTX News
- 5 days ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 6 days ago - MeiraGTx Reports First Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 10 days ago - MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - GlobeNewsWire
- 20 days ago - Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more - GlobeNewsWire
- 7 weeks ago - MeiraGTx Holdings: Gaining Regulatory Focus - Seeking Alpha
- 2 months ago - MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - Benzinga
- 2 months ago - MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates - GlobeNewsWire
- 2 months ago - MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - GlobeNewsWire